Ancom recall
This article was originally published in The Tan Sheet
Executive Summary
Availability of Ancom Anti-Hypertensive Compound Tablets has caused one adverse event so far, FDA says March 17. Tai Chien is recalling all 100-count bottles of the product because they contain several Rx ingredients, including diazepam, promethiazine, reserpine, which may pose health risks such as "sedation, depression and potentially life-threatening abnormalities of the blood," agency notes. Herbsland recalled same product in January (1"The Tan Sheet" Jan. 20, 2003, p. 8). Tablets are manufactured by Shanghai Pharmaceutical, sold at retail stories in New York City, online...
You may also be interested in...
Herbsland recall
All 100-tablet bottles of Ancom Anti-Hypertensive Compound Tablets recalled by Herbsland because they contain several Rx drug ingredients, including reserpine, diazepam, promethiazine, company says Jan. 17. Product is "unapproved new drug" and "poses possible serious health risks including sedation, depression and potentially life-threatening abnormalities of the blood," 1Herbsland press release says, although no adverse events have been reported. Sold through distributors, retail stores in the New York metropolitan area and over the Internet, Ancom tablets are labeled for anti-hypertensive use and come in white plastic bottles with an outer cardboard holding carton. Manufacturer is listed as Chinese firm Shanghai Pharmaceutical Industry...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.